Relay Therapeutics, Inc. Payments to Acquire Investments
Relay Therapeutics, Inc. (RLAY) reported Payments to Acquire Investments of $522.23 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireInvestments · last filed 2026-08-06
- Relay Therapeutics, Inc. payments to acquire investments for the quarter ending 2026-06-30 was $471.33M, a 5179.19% increase year-over-year.
- Relay Therapeutics, Inc. payments to acquire investments for the quarter ending 2026-03-31 was $50.90M, a 131.66% increase year-over-year.
- Relay Therapeutics, Inc. payments to acquire investments for the quarter ending 2025-12-31 was $34.00M, a 54.72% decline year-over-year.
- Relay Therapeutics, Inc. payments to acquire investments for the quarter ending 2025-09-30 was $58.08M, a 78.10% decline year-over-year.
- Relay Therapeutics, Inc. payments to acquire investments for fiscal 2025 was $122.97M, a 81.10% decline from fiscal 2024.
- Relay Therapeutics, Inc. payments to acquire investments for fiscal 2024 was $650.63M, a 68.76% increase from fiscal 2023.
- Relay Therapeutics, Inc. payments to acquire investments for fiscal 2023 was $385.54M, a 27.99% decline from fiscal 2022.
- Relay Therapeutics, Inc. payments to acquire investments for fiscal 2022 was $535.42M, a 45.40% decline from fiscal 2021.
| Period end | Payments to Acquire Investments 3 month | Payments to Acquire Investments 6 month | Payments to Acquire Investments 9 month | Payments to Acquire Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $471.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $522.23M 10-Q · filed 2026-08-06 | $556.22M derived: sum of 3 quarters · filed 2026-08-06 | $614.30M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $50.90M 10-Q · filed 2026-05-05 | $84.89M derived: sum of 2 quarters · filed 2026-05-05 | $142.97M derived: sum of 3 quarters · filed 2026-05-05 | $151.90M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $34.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $92.07M derived: sum of 2 quarters · filed 2026-02-26 | $101.00M derived: sum of 3 quarters · filed 2026-08-06 | $122.97M 10-K · filed 2026-02-26 |
| 2025-09-30 | $58.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $67.00M derived: sum of 2 quarters · filed 2026-08-06 | $88.97M 10-Q · filed 2025-11-06 | $164.05M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $8.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $30.90M 10-Q · filed 2026-08-06 | $105.97M derived: sum of 3 quarters · filed 2026-08-06 | $371.11M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $21.97M 10-Q · filed 2026-05-05 | $97.05M derived: sum of 2 quarters · filed 2026-05-05 | $362.18M derived: sum of 3 quarters · filed 2026-05-05 | $481.82M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $75.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $340.21M derived: sum of 2 quarters · filed 2026-02-26 | $459.85M derived: sum of 3 quarters · filed 2026-02-26 | $650.63M 10-K · filed 2026-02-26 |
| 2024-09-30 | $265.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $384.77M derived: sum of 2 quarters · filed 2025-11-06 | $575.55M 10-Q · filed 2025-11-06 | $712.37M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $119.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $310.42M 10-Q · filed 2025-08-07 | $447.23M derived: sum of 3 quarters · filed 2026-02-26 | $531.99M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $190.78M 10-Q · filed 2025-05-05 | $327.60M derived: sum of 2 quarters · filed 2026-02-26 | $412.35M derived: sum of 3 quarters · filed 2026-02-26 | $478.51M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $136.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $221.57M derived: sum of 2 quarters · filed 2026-02-26 | $287.73M derived: sum of 3 quarters · filed 2026-02-26 | $385.54M 10-K · filed 2026-02-26 |
| 2023-09-30 | $84.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $150.91M derived: sum of 2 quarters · filed 2024-11-06 | $248.73M 10-Q · filed 2024-11-06 | $576.37M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | $66.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $163.97M 10-Q · filed 2024-08-06 | $491.62M derived: sum of 3 quarters · filed 2025-02-26 | $547.45M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | $97.81M 10-Q · filed 2024-05-02 | $425.46M derived: sum of 2 quarters · filed 2025-02-26 | $481.29M derived: sum of 3 quarters · filed 2025-02-26 | $505.54M derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | $327.64M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $383.47M derived: sum of 2 quarters · filed 2025-02-26 | $407.73M derived: sum of 3 quarters · filed 2025-02-26 | $535.42M 10-K · filed 2025-02-26 |
| 2022-09-30 | $55.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $80.09M derived: sum of 2 quarters · filed 2023-11-02 | $207.78M 10-Q · filed 2023-11-02 | $534.81M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $24.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $151.94M 10-Q · filed 2023-08-08 | $478.98M derived: sum of 3 quarters · filed 2024-02-22 | $486.37M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $127.69M 10-Q · filed 2023-05-04 | $454.72M derived: sum of 2 quarters · filed 2024-02-22 | $462.12M derived: sum of 3 quarters · filed 2024-02-22 | $489.04M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $327.03M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $334.43M derived: sum of 2 quarters · filed 2024-02-22 | $361.35M derived: sum of 3 quarters · filed 2024-02-22 | $980.66M 10-K · filed 2024-02-22 |
| 2021-09-30 | $7.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $34.31M derived: sum of 2 quarters · filed 2022-11-03 | $653.63M 10-Q · filed 2022-11-03 | $779.99M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $26.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $646.24M 10-Q · filed 2022-08-04 | $772.60M derived: sum of 3 quarters · filed 2023-02-23 | $841.59M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $619.32M 10-Q · filed 2022-05-05 | $745.68M derived: sum of 2 quarters · filed 2023-02-23 | $814.67M derived: sum of 3 quarters · filed 2023-02-23 | $830.17M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $126.36M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $195.35M derived: sum of 2 quarters · filed 2023-02-23 | $210.85M derived: sum of 3 quarters · filed 2023-02-23 | $266.45M 10-K · filed 2023-02-23 |
| 2020-09-30 | $68.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $84.49M derived: sum of 2 quarters · filed 2021-11-10 | $140.10M 10-Q · filed 2021-11-10 | $229.08M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $15.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $71.10M 10-Q · filed 2021-08-12 | $160.08M derived: sum of 3 quarters · filed 2022-02-24 | $249.62M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $55.61M 10-Q · filed 2021-05-13 | $144.59M derived: sum of 2 quarters · filed 2022-02-24 | $234.13M derived: sum of 3 quarters · filed 2022-02-24 | |
| 2019-12-31 | $88.98M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $178.52M derived: sum of 2 quarters · filed 2022-02-24 | $553.52M 10-K · filed 2022-02-24 | |
| 2019-09-30 | $89.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $464.54M 10-Q · filed 2020-11-12 | ||
| 2019-06-30 | $375.00M 10-Q · filed 2020-08-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |